BTIG analyst Mark Massaro lowered the firm’s price target on Akoya Biosciences to $6 from $9 and keeps a Buy rating on the shares. The company’s Q1 earnings miss and guidance cut were “tough”, but most of its challenges look “transitory”, even though Akoya would likely need a “big recovery” in the second half of the year to achieve its updated targets, the analyst tells investors in a research note. Akoya also saw a temporary interruption as it moved its reagent manufacturing in-house in Q1, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKYA:
- AKYA Earnings this Week: How Will it Perform?
- Akoya, NeraCare enter exclusive agreement for personalized therapy selection
- Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients
- Akoya Biosciences opens Operations and Manufacturing Center in Marlborough
- Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts